Roth/MKM Starts Coverage on BioHarvest Sciences with Buy Rating
Roth/MKM has initiated coverage of BioHarvest Sciences (BHST) with a buy rating and a $10.00 price target, implying roughly 125% upside from the current share price of $4.45. The analyst highlights the company’s proprietary Botanical Synthesis platform, anticipated expansion of CDMO partnerships, an expected shift to positive annual cash flow in 20…